Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Graves' Orbitopathy~* Moderate-severe GO According to EUGOGO statements, patients with moderate-severe GO usually have any one or more of the following：moderate or severe soft tissue involvement, exophthalmos≥3mm above normal for race and gender, inconstant, or constant diplopia.~* Clinical activity score ≥ 3~* Being euthyroid for at least 1 month before the date of inclusion~* Must be able to swallow tablets~* Written informed consent is obtained~Exclusion Criteria:~* Mild Graves' Orbitopathy~* Sight-threatening Graves' Orbitopathy~* Clinical activity score \< 3~* Previous treatment for GO Oral steroids, intravenous steroids, radiotherapy~* Pregnant females as determined by positive (serum or urine) Human chorionic gonadotropin (hCG) test at screening or prior to dosing, or lactating females~* Uncontrolled diabetes or hypertension~* History of mental / psychiatric disorder~* Hepatic dysfunction (Albumin (Alb),Aspartate Transaminase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility)~* Renal impairment (Urea and Creatinine levels must be within normal range)~* Doxycycline allergy or intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Tablets Doxycycline 50 mg PO per day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).